Skip to content Skip to footer

Waiv Partners with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery for ADC Program

Shots: Waiv has collaborated with Daiichi Sankyo to lead digital pathology biomarker discovery for an ADC program, leveraging its end-to-end computational pathology platform Waiv will use its platform to analyze early-phase trial data, incl. tumor microenvironment profiling across H&E & IHC slides, biomarker discovery, & outcome prediction, aimed at identifying biomarkers of treatment response The…

Read more

Precision Medicine in Cancer Treatment: Revolutionizing Patient Care Through Personalized Approaches

Precision medicine has emerged as a transformative approach in cancer treatment, moving away from the traditional one-size-fits-all methodology toward highly individualized therapeutic strategies. This paradigm shift recognizes that each patient's cancer is unique, with distinct genetic profiles, molecular characteristics, and treatment responses that require tailored approaches. By leveraging advanced genomic technologies, biomarker identification, and sophisticated…

Read more